Business

Federal Reserve appointments including Stephen Miran's advancement and Lisa Cook's temporary retention, unexpected August wholesale price declines, President Trump's aggressive tariff proposals against China and India, and Kamala Harris's criticism of the Democratic party's strategy define the current landscape of US politics, economy, and trade policy.

The EU's move to freeze funding to Israel amidst the Gaza conflict, Israel's expanded military actions into Qatar, NATO forces shooting down Russian drones over Poland, and UN progress towards restarting nuclear inspections in Iran underscore a day of heightened global tensions and diplomatic efforts.

Starmer's government facing scrutiny over appointments, Chancellor Reeves's commitment to reducing regulators, plans for Kent and Greenwich universities to merge, and growing concerns over youth economic inactivity highlight key developments and challenges within the UK's economic and political sphere.

China's economic indicators including deflation and rising bond yields, slowing retail sales for major fashion brands like Zara and Primark due to tariffs and political turmoil, **significant M&A activity in mining and retail, and Singapore's strategic move into green finance** illustrate a diverse range of international economic shifts and corporate strategies.

JPMorgan and Fifth Third facing potential losses from a subprime auto lender, SEC crackdowns on 'pump-and-dump' schemes, the resurgence of US IPO hopefuls, and sinking shares in bitcoin hoarders amid a souring 'crypto treasury' mania characterize a busy period for financial markets and regulatory bodies.

Oracle's shares skyrocketing from massive AI deals and Larry Ellison becoming the world's richest person, Amazon's Zoox and other robotaxi services expanding, and PsiQuantum raising significant funds for quantum computing underscore a rapidly advancing and highly competitive technology and AI landscape.

Ozempic maker Novo Nordisk's plans to cut 9,000 jobs, Merck's decision to scrap a major UK drug research center, and US drugmakers lobbying against proposed White House curbs on China reveal a pharmaceutical sector undergoing significant restructuring and facing geopolitical pressures.

Previous
Next